![]() | Clinical UM Guideline |
| Subject: | Injection Treatment for Morton’s Neuroma | ||
| Guideline #: | CG-SURG-25 | Current Effective Date: | 01/13/2010 |
| Status: | Reviewed | Last Review Date: | 11/19/2009 |
| Description |
Morton's neuroma is a common, paroxysmal neuralgia affecting the web spaces of the toes, typically the third. The pain is often so debilitating that individuals become anxious about walking or even putting their foot to the ground. Insoles, corticosteroid injections, excision of the nerve, transposition of the nerve and neurolysis of the nerve are commonly used treatments (Cochrane, 2004).
| Clinical Indications |
Medically Necessary:
Injections of sclerosing (neurolytic), anesthetic or steroid agents are considered medically necessary for treatment of Morton's neuroma when all of the following conservative therapies have failed:
| Coding |
The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.
| CPT | |
| 64455 | Injection(s), anesthetic agent and/or steroid, plantar common digital nerve(s) (eg, Morton's neuroma) |
| 64632 | Destruction by neurolytic agent; plantar common digital nerve |
| ICD-9 Diagnosis | |
| 355.6 | Lesion of plantar nerve (Morton's metatarsalgia, neuralgia, or neuroma) |
| Discussion/General Information |
Typically, a neuroma is a benign tumor of a nerve characterized by exuberant proliferation of nerve endings. Morton's neuroma is not actually a tumor, but a thickening of the tissue that surrounds the digital nerve leading to the toes. It occurs as the nerve passes under the ligament connecting the toe bones (metatarsals) in the forefoot. The cause of Morton's neuroma is not clear and most frequently develops between the third and fourth toes. Possible etiologies include nerve entrapment, the aberrant anatomy of the plantar nerve in this location, structural/mechanical foot abnormalities, trauma or excessive pressure.
Multiple treatment approaches have been utilized for Morton's neuroma. These include conservative care, such as othotics, padding, and alternative shoe styles to relieve the pressure on the forefoot. More invasive treatments include sclerosing/anesthetic/steroid injections and surgical excision of the painful nerve. The available literature contains varied conclusions. Thomson et al, in a review of the current literature, cited that there is insufficient evidence with which to assess the effectiveness of surgical and non-surgical interventions for Morton's neuroma and that well designed trials are needed to begin to establish an evidence base for the treatment of Morton's neuroma pain (Thomson, 2001). Serial ethanol injection therapy has been reported to be an effective alternative to surgical excision (Fanucci, 2004). However, despite wide adoption of this treatment, no randomized, double blinded, placebo-controlled study exists to verify the efficacy of this treatment in comparison to longer standing similar therapies, such as corticosteroid injection.
The American College of Foot and Ankle Surgeons (ACFAS) addresses conservative and injection treatment of Morton's neuroma in their 2009 practice guideline: Diagnosis and treatment of forefoot disorders - Morton's intermetatarsal neuroma. Conservative care focuses on elimination of pressure and irritation of the nerve. Injection therapies for pain relief include local anesthetic blocks, corticosteroids and neurolytic alcohol injections. They caution that overuse of cortisone injections can result in atrophy of the plantar fat pad as well as joint subluxation.
A randomized, double-blind, placebo controlled clinical trial, Comparison of Corticosteroid and Ethanol Injection Therapy in the Treatment of Morton's Neuroma continues to recruit patients. In this trial, 120 patients will be randomized to three treatments, specifically lidocaine injection, corticosteroid injection, or ethanol injection. Outcomes will be assessed at 3, 6 and 12 month time points using validated questionnaires as well as a non-validated disease specific questionnaire. Primary endpoint will be graded change in the physical function portion of the Medical Outcomes Study short form (SF-36) (NCT00284583).
| References |
Peer Reviewed Publications:
Government Agency, Medical Society and Other Authoritative Publications:
| Index |
Intermetatarsal Neuroma
Morton's Neuroma
| History |
| Status | Date | Action |
| Reviewed | 11/19/2009 | Medical Policy & Technology Assessment Committee (MPTAC) review. Discussion and references updated. Place of service removed. |
| Reviewed | 11/20/2008 | MPTAC review. References updated. Coding section updated to include 01/01/2009 CPT changes, removed HCPCS S2135 deleted 12/31/2008. |
| Reviewed | 11/29/2007 | MPTAC review. References updated. |
| Revised | 12/07/2006 | MPTAC revision. Deleted surgical procedures from criteria. References updated. |
| New | 09/14/2006 | MPTAC initial guideline development. |